Synologic is a clinical-stage biopharmaceutical company developing living medicines to treat a range of metabolic diseases, inflammatory diseases, and cancers. The technology platform uses synthetic biology to engineer beneficial bacteria, or probiotics, that alter the composition of the gut microbiome to restore proper metabolic functions. The populations of bacteria comprising the gut microbiome play a critical role in regulating the human immune system, metabolic function, brain health, and more. The company was founded in 2007 and is headquartered in Boston, Massachusetts.
The majority of the company's drug candidates are in pre-clinical testing, although its lead drug candidate is in phase 2 trials. Synlogic calls its probiotics Synthetic Biotics. The pipeline as of July, 2nd, 2018:
Immune oncology (three programs)
Inflammatory bowel disease
Maple Syrup urine disease
Urea cycle disorder
In December 2017 Synlogic and Ginkgo Bioworks announced a collaboration to use the latter's industrial scale organism engineering platform to discover new drug candidates.
In May 2017 Synlogic entered into a merger agreement with Mirna Therapeutics under which Synlogic merged with a wholly owned subsidiary of Mirna in an all-stock transaction. The merged company continued under the Synlogic name.